ExpreS2ion Biotech

The presentation poster titled "Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis" concludes, that:

• ES2B-C001 vaccination inhibited the onset, growth, and metastatic spread of HER-2 positive mammary carcinomas in mice.

• The vaccine induced strong and persistent antibody responses that inhibited human HER-2+ breast and gastric cancer cells in vitro.

• ES2B-C001 is a promising candidate vaccine for the therapy of human tumours expressing HER-2. Preclinical results warrant further development towards human clinical studies.

A copy of the poster can be found at the company webpage at https://expres2ionbio.com/meet-us/

Certified Adviser

Svensk Kapitalmarknadsgranskning AB